Skip to main content

Repare Therapeutics (RPTX) Gets a Buy from TD Cowen

Tipranks - Tipranks - Wed May 14, 2025

TD Cowen analyst Marc Frahm maintained a Buy rating on Repare Therapeutics (RPTX – Research Report) yesterday. The company’s shares closed yesterday at $1.43.

Confident Investing Starts Here:

According to TipRanks, Frahm is a 3-star analyst with an average return of 0.9% and a 36.70% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Kymera Therapeutics, Janux Therapeutics Inc, and Xilio Therapeutics.

Currently, the analyst consensus on Repare Therapeutics is a Moderate Buy with an average price target of $5.00.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $4.29 and a one-year low of $0.89. Currently, Repare Therapeutics has an average volume of 313.6K.

Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RPTX in relation to earlier this year. Most recently, in March 2025, Lloyd Mitchell Segal, the President & CEO of RPTX sold 21,179.00 shares for a total of $24,144.06.

Read More on RPTX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).